China Medical System Holdings Limited (HKG:0867)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 31.73B |
| Revenue (ttm) | 8.61B |
| Net Income (ttm) | 1.81B |
| Shares Out | 2.42B |
| EPS (ttm) | 0.75 |
| PE Ratio | 17.55 |
| Forward PE | 15.92 |
| Dividend | 0.29 (2.23%) |
| Ex-Dividend Date | Aug 29, 2025 |
| Volume | 6,535,528 |
| Average Volume | 5,841,353 |
| Open | 13.60 |
| Previous Close | 13.60 |
| Day's Range | 13.03 - 13.74 |
| 52-Week Range | 6.71 - 15.63 |
| Beta | 1.01 |
| RSI | 38.12 |
| Earnings Date | Nov 19, 2025 |
About HKG:0867
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ... [Read more]
Financial Performance
In 2024, HKG:0867's revenue was 7.47 billion, a decrease of -6.79% compared to the previous year's 8.01 billion. Earnings were 1.62 billion, a decrease of -32.54%.
Financial numbers in CNY Financial StatementsNews
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodeg...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
On Wednesday, Alpha Cognition Inc. (NASDAQ: ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Zun...